ArticleRheumatology (Oxford, England)2025
Lung transplantation outcomes of patients with interstitial pneumonia with autoimmune features: a single-centre retrospective cohort study.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInterstitial pneumonia with autoimmune features (IPAF) describes patients with interstitial lung disease (ILD) and autoimmune features without meeting criteria for a specific rheumatic disease. No longitudinal data exist on post-transplant outcomes in IPAF patients. We compared baseline demographics, pre-transplant characteristics and post-transplant outcomes between IPAF and idiopathic pulmonary fibrosis (IPF) patients undergoing double lung transplantation.
methodsWe retrospectively analysed lung transplant recipients with ILD in British Columbia between 1 January 2014 and 30 April 2024. Diagnoses of IPAF and IPF were made by multidisciplinary review. Continuous variables were analysed using the Mann-Whitney U test, categorical variables with Fisher's exact test, and survival using Kaplan-Meier analysis.
resultsWe identified 20 IPAF and 64 IPF patients. IPAF patients were more likely female (50% vs 17%, P = 0.006), on pre-transplant immunosuppression (60% vs 6.3%, P < 0.001) and were less likely to receive antifibrotics (20% vs 64%, P < 0.001). No difference was seen in 1-year or cumulative survival, though survival curves diverged over time favouring IPAF. Post-transplant lung function, acute rejection, infection-related hospitalization, malignancy and chronic lung allograft dysfunction (CLAD) were similar, with non-usual interstitial pneumonia (UIP) IPAF exhibiting a survival advantage over IPF (100% vs 66%, P = 0.044). Explant pathology revealed more UIP patterns in IPF, while IPAF showed more non-specific interstitial pneumonia (NSIP) or unclassifiable patterns.
conclusionsPost-transplant survival, lung function and complication rates were comparable between IPAF and IPF patients at one year and the last follow-up. This is the first study to report both short- and long-term lung transplant outcomes in IPAF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.